Business
GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium
GB Sciences Declares A "Research Revolution" At Its "2018 Innovation In Medical Cannabis Therapies" Symposium.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Declares A \"Research Revolution\" At Its \"2018 Innovation In Medical Cannabis Therapies\" Symposium\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Declares A \"Research Revolution\" At Its \"2018 Innovation In Medical Cannabis Therapies\" Symposium\nPR Newswire\nLAS VEGAS, Dec. 14, 2018\n\n\n\nOn November 9th, GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation of future medical cannabis products.\n LAS VEGAS, Dec. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces the success of its first annual, \"Innovation in Medical Cannabis Therapies\" (IMCT) Symposium, held on Friday, November 9th at the \"Keep Memory Alive\" Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day's program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price. \nExperience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8308958-gb-sciences-2018-medical-cannabis-therapies-symposium/ \n\"The primary objective of GB Sciences' IMCT Symposium was to invite key stakeholders in the cannabis industry to talk about how we could better serve patients' needs in an open forum including patients, caregivers, patient advocates, physicians, nurses, researchers, technology manufacturers, growers, extractors, dispensary owners, regulators, and legislators,\" explained Dr. Andrea Small-Howard, CSO & Director of GB Sciences. \"Based on overwhelming attendee feedback, we consider the ICMT Symposium a great success in starting this critical dialogue and recruiting people from very diverse areas to join a movement that will improve cannabis-based medicines in the futur...